Injectable pharmaceutical drug delivery system can be used as an alternative to oral drug delivery system. An injection is considered a form of parenteral drug administration, and it allows the medication to be absorbed more rapidly.
Africa injectable drugs market is estimated to be valued at US$ 284.5 Mn in 2022 and expected to exhibit a CAGR of 4.7% during the forecast period (2022-2030).
Figure 1. Africa Injectable Drugs Market Share (%) in Terms of Value, by Molecule Type, 2022
The increasing prevalence of chronic diseases such as cardiovascular, diabetes, cancer, etc. is expected to drive the market growth during the forecast period.
Sedentary lifestyle and changes in dietary habits i.e. the consumption of fats and sugar-rich diet lead to an increase in cases of obesity and thereby increase the risk of cardiovascular diseases and diabetes. For instance, according to the International Diabetes Federation, in 2019, an estimated 19.4 million adults aged 20-79 years were living with diabetes in Africa.
|Base Year:||2021||Market Size in 2022:||US$ 284.5 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.7%||2030 Value Projection:||US$ 410.9 Mn|
Apotex Inc., Fresenius Kabi India Pvt. Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Gland Pharma Limited, hameln pharma gmbh, Merck & Co., Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and PANPHARMA S.A.
|Restraints & Challenges:||
Figure 2. Africa Injectable Drugs Market Share (%), by End User, 2022
Growing manufacturing facilities for pharmaceutical drugs are expected to drive the market growth during the forecast period.
The ever-growing number of healthcare practitioners leads to a surge in the demand for injectable drugs. For instance, in Africa estimated there were about 266,279 doctors in 2020. Thus, key market players are engaged in enhancing their manufacturing capabilities and strengthening their position in the market, which will drive the market growth. For instance, in sub-Saharan Africa, only Kenya, Nigeria, and South Africa have a relatively considerable industry with a significant number of manufacturing companies. Moreover, initiatives by governments and market players to develop a local drug industry in sub-Saharan Africa is expected to create a significant opportunity for the market players.
Africa Injectable Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.
The COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets.
Africa Injectable Drugs Market: Restraint
The major factors that hinder the growth of Africa injectable drugs market include the lack of funding for manufacturing injectable products. Lack of finances can also be a significant challenge to manufacturing injectable pharmaceuticals.
Major players operating in Africa injectable drugs market include Apotex Inc., Fresenius Kabi India Pvt. Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Gland Pharma Limited, hameln pharma gmbh, Merck & Co., Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and PANPHARMA S.A.
Injectable drugs are injected by various routes of administration, such as intravenous, intramuscular, sub-cutaneous, etc. to treat a number of diseases such as cardiovascular, respiratory, cancer, etc. Healthcare professionals can inject many medications into different parts of the body. They will decide the most appropriate route of access depending on the situation.
Rapid therapeutic effect of injectable drugs is leads to increase the demand for the injectable products. Thus, key market players are engaged in enhancing manufacturing facilities of pharmaceutical products and strengthening their market position in Africa. This, in turn, is expected to drive the market growth. For instance, the African Union Commission (AUC) and the United Nations Industrial Development Organization (UNIDO) developed a business plan to accelerate the implementation of the Pharmaceutical Manufacturing Plan for Africa (PMPA), with funding from the German government. Moreover, injectable drugs offer potential benefits to patients with human immunodeficiency virus (HIV) on anti-retroviral therapy (ART) in low-income settings in sub-Saharan Africa. This in turn to increase usage of injectable drugs to treat HIV patients and thereby drive the growth of market in Africa. Furthermore, surge in presence of branded formulations is anticipated to drive the growth of market. For instance, branded formulations for bupivacaine injection such as Macaine HCL, (0.5% for spinal injection), Macaine HCL, (0.5% for injection with Dextrose), and Macaine HCL, (0.5% injection) are available in African countries, majorly in South Africa. Major manufacturers in Africa such as Pharma-Q Holdings (Pty) Ltd. and Adcock Ingram Limited offer bupivacaine injection in South Africa and other countries in Africa. In addition, manufactures operating in the market are appointing a distributors and thus increases the number of suppliers. This in turn to propel the growth of market. For instance, online distributors/pharmacies such as Seif Pharmacy in Egypt offers Isoptin (5 mg / 2ml) in the country. Pharmaceutical suppliers such as Pharmachemie (Pty) Ltd. and Sanofi-Aventis South Africa (Pty) Ltd. supply Fludarabine brands to the Department of Health, South Africa
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.